CUCCI, Marie Angele
 Distribuzione geografica
Continente #
NA - Nord America 1501
EU - Europa 1242
AS - Asia 538
AF - Africa 51
Continente sconosciuto - Info sul continente non disponibili 11
SA - Sud America 3
OC - Oceania 2
Totale 3348
Nazione #
US - Stati Uniti d'America 1484
CN - Cina 342
IT - Italia 228
UA - Ucraina 195
GB - Regno Unito 177
DE - Germania 138
SE - Svezia 112
FI - Finlandia 108
FR - Francia 107
KR - Corea 99
PL - Polonia 63
AT - Austria 53
VN - Vietnam 45
SN - Senegal 28
IN - India 24
GR - Grecia 18
CA - Canada 16
MU - Mauritius 15
EU - Europa 11
NL - Olanda 10
ET - Etiopia 7
JP - Giappone 6
BE - Belgio 5
HK - Hong Kong 5
IE - Irlanda 5
TR - Turchia 5
ES - Italia 4
UZ - Uzbekistan 4
CH - Svizzera 3
IR - Iran 3
PT - Portogallo 3
RO - Romania 3
BG - Bulgaria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
RU - Federazione Russa 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
HR - Croazia 1
ID - Indonesia 1
IL - Israele 1
IQ - Iraq 1
MK - Macedonia 1
MX - Messico 1
PH - Filippine 1
Totale 3348
Città #
Beijing 199
Fremont 139
Chandler 130
Ann Arbor 120
Fairfield 100
Jacksonville 97
Torino 91
Houston 88
Medford 87
Dearborn 86
Princeton 68
Warsaw 62
Villeurbanne 57
Woodbridge 55
Vienna 52
Wilmington 45
Ashburn 37
Dong Ket 37
Cambridge 34
Milan 34
Verona 27
Seattle 23
Nyköping 20
Pisa 18
Redwood City 17
Boston 15
Hefei 12
Norwalk 12
San Diego 12
Falls Church 11
Hebei 10
Kunming 10
Wuhan 10
Athens 9
Nanjing 9
Xian 9
Lachine 8
Shanghai 8
Guangzhou 7
Jinan 7
Hangzhou 6
Nanchang 6
Central District 5
Gloucester 5
Guiyang 5
Redmond 5
Rome 5
Turin 5
Valdagno 5
Brussels 4
Düsseldorf 4
Toronto 4
Baotou 3
Coral Gables 3
Los Angeles 3
Napoli 3
Nürnberg 3
Shenyang 3
Ariano Irpino 2
Chuncheon 2
Dublin 2
Duncan 2
Durham 2
Fuzhou 2
Gravina In Puglia 2
Groningen 2
Jiaxing 2
Kharkiv 2
London 2
Montevideo 2
Niagara Falls 2
Osaka 2
Seoul 2
Sevilla 2
Stavanger 2
Taiyuan 2
Taizhou 2
Tianjin 2
Zhengzhou 2
Altamura 1
Augusta 1
Aurora 1
Avezzano 1
Barcelona 1
Berlin 1
Birmingham 1
Bochum 1
Buenos Aires 1
Buffalo 1
Calgary 1
Chandigarh 1
Changsha 1
Chongqing 1
Clearwater 1
Cluj-Napoca 1
Collegno 1
Columbus 1
Dallas 1
Des Moines 1
Dubai 1
Totale 2012
Nome #
Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A 214
Post-translational inhibition of YAP oncogene expression by 4-hydroxynonenal in bladder cancer cells 180
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 144
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 130
T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment 117
The Potential Therapeutic Target Nrf2 in Childhood Brain Tumors 106
Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression 102
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study 92
Treatment response to interferon beta: Biological (MxA protein or IL-10 mRNA level) or MRI indicators? 84
Lipid peroxidation-derived aldehydes, 4-hydroxynonenal and malondialdehyde in aging-related disorders 72
Glutathione-responsive cyclodextrin-nanosponges as drug delivery systems for doxorubicin: Evaluation of toxicity and transport mechanisms in the liver 66
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study 65
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials 61
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b 60
Is the combination of different treatment responseindicators useful to identify patients with a sub-optimal response to interferon beta? 55
La dose ottimale di interferone beta: studio preliminare sulla tolleranza della dose di 375 microgrammi di interferone beta-1b 54
A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b 54
Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation 53
Carbosilane dendrimers loaded with sirna targeting nrf2 as a tool to overcome cisplatin chemoresistance in bladder cancer cells 52
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 51
T-helper (Th) 22, a newly identified lymphocyte subset, increases 1-3 months before an MS relapse and it is not sensitive to INF beta 49
Mxa protein in ms patients treated with different doses of ifn beta-1b (the optims study): correlation with treatment response, ifn beta dose, and neutralizing antibodies (nab)occurrence 48
The OPTimization of interferon for MS (OPTIMS) study. A multicenter trial comparing two different doses (250 and 375 mcg) of IFN beta-1b 48
High-dose interferon-beta-1b (500 mcg every-other-day, subcutaneously) treatment in MS patients. Long-term evaluation and longitudinal comparison with preceding treatment with lower IFN beta dose 48
Novel tetrahydroacridine derivatives with iodobenzoic moieties induce G0/G1 cell cycle arrest and apoptosis in A549 non-small lung cancer and HT-29 colorectal cancer cells 48
Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients. 47
Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD). 47
Using biological (mxa protein or il-10 mrna level) or mri indicators for assessing treatment response to interferon-beta 47
Anti-Gm1 And Anti-Sulfatide Antibodies In Polyneuropathies. Threshold Titers And Accuracy 46
Mxa protein and interleukin-10 (il-10) leukocyte production and anti-ifn neutralizing antibody(nab) occurrence in relapsing remitting multiple sclerosis (rrms) patients treated with different doses of interferon (ifn) beta- 1b 46
Evaluation of mitochondrial manganese in leukocyte of multiple sclerosis patients. 45
NAB titre in patients treated with different doses of ifn beta-1b: preliminary results from the optims study. 45
Is it possible to reduce the dose of interferon (IFN) beta in MS patients with a prolonged MRI-confirmed absence of disease activity? 45
Long Term immunological alemtuzumab effect: increase in Tregsuppressor function 44
A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study. 43
Control of oxidative stress in cancer chemoresistance: spotlight on Nrf2 role 43
To evaluate anti-interferon (ifn) neutralizing antibody (nab) in relapsing remitting (rr) ms patients treated over the long term with an ifn beta-1b dose higher than that currently approved. 42
Autoimmunity profile in interferon beta- 1a treated multiple sclerosis patients. the auprin study: comparision of 2 different dosage of subcutaneous interferon-beta 1a. 42
High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study 41
Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia 41
Autoimmunity profile in interferon beta- 1a treated Multiple Sclerosis patients. the auprin study: comparison of 2 different dosage of subcutaneous interferon-beta 1a 39
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 38
Mxa protein, interleukin-10 and neutralising antibody in MS patients treated with different doses of Interferon-Beta-1b 36
Secondary progressive (sp) ms: immunological effects of intravenous immunoglobuln g (ivig) therapy 36
Every-other-day interferon beta-1b compared with once weekly interferon beta 1-a in ms. further analysis of treatment effect on mri activity and neutralizing antibodies (nabs) in the INCOMIN trial 36
Autoimmunity profile in interferon beta-1a treated Multiple Sclerosis patients. The AUPRIN Study: comparison of 2 different dosages of subcutaneous interferon beta-1a 36
Mxa protein: correlation with magnetic resonance imaging response in relapsing-remitting multiple sclerosis patients treated with two different ifn beta doses 33
Mxa protein, interleukin-10 (il-10) and neutralizing antibody (nab) in relapsing- remitting (rr) multiple sclerosis (ms) patients treated with different doses of inteferon (ifn) beta- 1b. 33
High-dose (375 mcg) interferon beta-1b treatment of multiple sclerosis and neutralising antibodies. Long-term follow-up 33
IFN beta-1b 500 mcg every-other-day, subcutaneously in MS patients. Tolerability, clinical and MRI results after one year of treatment 33
IFN beta-1b in multiple sclerosis: comparing two different doses (the Optims Study). 32
Increasing dose of ifn beta 1b in ms patients: preliminary nab results from the optims study. 31
MX protein and neutralizing interferon antibodies in relapsing remitting multiple sclerosis patients treated with interferon beta-1b: correlation with clinical and mri efficacy 31
Interferon beta-1b 500 mcg every-other-day, subcutaneously in ms patients. Tolerability, clinical and mri results after one year of treatment 31
Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism 30
Real-time rt-pcr determination of mrna levels of cytokine, chemokine and chemokine receptors, in patients treated with ifn beta 1b: correlation with mri response and evaluation of a prognostic marker in ms. 29
Interferon beta-1b 500 mcg every-other-day in ms patients. Clinical and mri results 29
Looking for treatment response indicator. real- time rt-pcr determination of mrna levels of cytokine, chemokine and chemokine receptors in Multiple Sclerosis patients treated with ifn beta 1b: correlation with mri response 27
Long-term evaluation of safety and efficacy of mitoxantrone therapy in secondary progressive Multiple Sclerosis patients. 27
Indicators of treatment response to interferon beta in ms. mxa protein, il-10 mrna or mri? 27
MRNA levels of cytokines, chemokines and chemokine receptors as indicator of treatment response in Multiple Sclerosis patients treated with interferon-beta 1b 26
Mitoxantrone safety in secondary progressive Multiple Sclerosis patients 24
PRO-INFLAMMATORY CYTOKINE AND CHEMOKINE MRNA BLOOD LEVEL IN MULTIPLE SCLEROSIS IS RELATED TO TREATMENT RESPONSE AND INTERFERON-BETA DOSE 24
Six year prospective immunological study of alemtuzumab treated patients: identification of markers of the clinical response 23
Oxidative stress-related mechanisms in melanoma and in the acquired resistance to targeted therapies 23
Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresistance in pancreatic cancer cells 18
Ultrasound-Responsive Nrf2-Targeting siRNA-Loaded Nanobubbles for Enhancing the Treatment of Melanoma 17
Totale 3519
Categoria #
all - tutte 4922
article - articoli 0
book - libri 0
conference - conferenze 3055
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7977


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018384 0000 03 1148 1447477
2018/2019325 221610 1563 451 9467136
2019/2020694 18174865 5997 9046 89803649
2020/2021628 78506133 3639 3327 103355182
2021/2022730 24171943 3542 2835 4881158200
2022/2023247 109931926 00 00 0000
Totale 3519